CN103249429A - 缓冲的眼用组合物以及使用其的方法 - Google Patents

缓冲的眼用组合物以及使用其的方法 Download PDF

Info

Publication number
CN103249429A
CN103249429A CN2011800544664A CN201180054466A CN103249429A CN 103249429 A CN103249429 A CN 103249429A CN 2011800544664 A CN2011800544664 A CN 2011800544664A CN 201180054466 A CN201180054466 A CN 201180054466A CN 103249429 A CN103249429 A CN 103249429A
Authority
CN
China
Prior art keywords
compositions
described method
ophthalmic composition
polypeptide
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800544664A
Other languages
English (en)
Chinese (zh)
Inventor
塔玛·滕宁鲍姆
利奥拉·布赖曼-维克斯曼
尤瓦尔·萨吉夫
奥芙拉·利维-哈查姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healor Ltd
Original Assignee
Healor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healor Ltd filed Critical Healor Ltd
Priority to CN201510134566.8A priority Critical patent/CN104758921A/zh
Publication of CN103249429A publication Critical patent/CN103249429A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2011800544664A 2010-11-08 2011-11-08 缓冲的眼用组合物以及使用其的方法 Pending CN103249429A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510134566.8A CN104758921A (zh) 2010-11-08 2011-11-08 缓冲的眼用组合物以及使用其的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41146610P 2010-11-08 2010-11-08
US41146410P 2010-11-08 2010-11-08
US61/411,464 2010-11-08
US61/411,466 2010-11-08
PCT/IL2011/000866 WO2012063237A2 (en) 2010-11-08 2011-11-08 Buffered ophthalmic compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510134566.8A Division CN104758921A (zh) 2010-11-08 2011-11-08 缓冲的眼用组合物以及使用其的方法

Publications (1)

Publication Number Publication Date
CN103249429A true CN103249429A (zh) 2013-08-14

Family

ID=46051349

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510134566.8A Pending CN104758921A (zh) 2010-11-08 2011-11-08 缓冲的眼用组合物以及使用其的方法
CN2011800544664A Pending CN103249429A (zh) 2010-11-08 2011-11-08 缓冲的眼用组合物以及使用其的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510134566.8A Pending CN104758921A (zh) 2010-11-08 2011-11-08 缓冲的眼用组合物以及使用其的方法

Country Status (8)

Country Link
US (2) US20120264681A1 (enExample)
EP (2) EP2637684A4 (enExample)
JP (1) JP2013543862A (enExample)
CN (2) CN104758921A (enExample)
AU (1) AU2011327785A1 (enExample)
CA (1) CA2812164A1 (enExample)
RU (1) RU2013117209A (enExample)
WO (1) WO2012063237A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104940904A (zh) * 2015-05-27 2015-09-30 北京爱特普科技有限公司 一种腔体粘膜微生态调节剂及其制备方法
CN109640966A (zh) * 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
WO2024148654A1 (zh) * 2023-01-09 2024-07-18 维眸生物科技(浙江)有限公司 一种含vvn539的眼用组合物及其用途

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CA2760562C (en) 2009-05-01 2016-07-19 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
EP2637684A4 (en) 2010-11-08 2014-05-07 Healor Ltd BUFFERED OPHTHALMIC COMPOSITIONS AND USER METHOD THEREFOR
US20130296250A1 (en) * 2011-01-11 2013-11-07 Healor Ltd. Method for treatment of psoriasis
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
PT3811943T (pt) 2013-03-15 2023-03-15 Aerie Pharmaceuticals Inc Composto para uso no tratamento de distúrbios oculares
WO2014179440A1 (en) * 2013-04-30 2014-11-06 University Of Southern California Accelerated healing of eye injuries by angiotensin peptides
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
WO2016064078A1 (ko) * 2014-10-22 2016-04-28 주식회사 지트리비앤티 티모신 베타 4를 함유하는 조성물 및 이를 포함하는 약학적 제형
EP3011959A1 (en) 2014-10-23 2016-04-27 Santen SAS Quaternary ammonium compound for use as an inhibitor of protein kinase C alpha
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
KR20170021667A (ko) * 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
EP3313413B1 (en) 2015-09-28 2024-12-04 Azura Ophthalmics Ltd Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
US11040062B2 (en) 2016-04-14 2021-06-22 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
JP6943707B2 (ja) * 2016-08-23 2021-10-06 積水化学工業株式会社 水溶性樹脂組成物及び水溶性樹脂フィルム
US10918699B2 (en) 2017-03-22 2021-02-16 Michael C. Struck Therapeutic treatment for neurotrophic keratopathy
SG11201908179UA (en) 2017-03-31 2019-10-30 Aerie Pharmaceuticals Inc Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US20190290736A1 (en) 2017-10-19 2019-09-26 Fourward Technology, LLC Topical composition for improved healing of open wounds
WO2020056345A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
JP2020075918A (ja) * 2018-11-02 2020-05-21 千寿製薬株式会社 角膜上皮創傷治癒促進用の眼科用組成物
WO2020172260A1 (en) * 2019-02-20 2020-08-27 Buice Mona E Topical composition for improved healing of ocular ailments
US10799481B1 (en) * 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
CN115279458A (zh) 2020-01-10 2022-11-01 阿祖拉眼科有限公司 组合物和敏感性说明
CN111610334A (zh) * 2020-05-18 2020-09-01 山东省肿瘤防治研究院（山东省肿瘤医院） 一种基于细胞大小过滤识别肿瘤患者外周血循环肿瘤细胞的方法
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124553A1 (en) * 2007-05-04 2009-05-14 Mochly-Rosen Daria D Suppression of inflammation associated with transplantation using an epsilon PKC inhibitor
WO2010029350A1 (en) * 2008-09-09 2010-03-18 University Of East Anglia Treatment of fibrotic eye disorders
US20100092452A1 (en) * 2008-05-07 2010-04-15 The Regents Of The University Of California Replenishment and Enrichment of Ocular Surface Lubrication

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549747A (en) 1968-02-20 1970-12-22 Flow Pharma Inc Contact lens wetting solution and method of using same
US3947573A (en) 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
US3856919A (en) 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US3767788A (en) 1970-06-08 1973-10-23 Burton Parsons Chemicals Inc Ophthalmic solution
US3767789A (en) 1971-06-21 1973-10-23 Burton Parsons & Co Inc Method of providing a synthetic mucus in vivo
US3907985A (en) 1973-07-27 1975-09-23 Burton Parsons And Company Inc Polystyrene sulfonate containing opthalmic solutions
US3987163A (en) 1973-07-27 1976-10-19 Burton, Parsons And Company, Inc. Polystyrene sulfonate containing opthalmic solutions
US4029817A (en) 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
US3920810A (en) 1974-04-23 1975-11-18 Burton Parsons And Company Inc Polyacrylamide containing ophthalmic solutions
US4120949A (en) 1977-10-05 1978-10-17 Cooper Laboratories, Inc. Ophthalmic solution
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
JP3059092B2 (ja) * 1995-11-15 2000-07-04 田辺製薬株式会社 ドライアイおよびドライアイを原因とする疾患の予防・治療剤
US20060258562A1 (en) 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
NZ545318A (en) * 2003-07-15 2009-06-26 Univ Bar Ilan Pharmaceutical compositions for healing wounds comprising insulin and PKC alpha inhibitor
ZA200601089B (en) * 2003-08-07 2007-05-30 Hearlor Ltd Pharmaceutical compositions and methods for accelerating wound healing
CA2625674C (en) * 2005-08-29 2015-04-14 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
ITMI20052036A1 (it) * 2005-10-26 2007-04-27 Professional Dietetics Srl Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato
US8664176B2 (en) * 2006-10-20 2014-03-04 Celldex Therapeutics, Inc. Treatment for age-related macular degeneration and other diseases of the eye
US20080292726A1 (en) * 2007-01-23 2008-11-27 Bernstein Lawrence R Ophthalmic gallium compositions and methods of their use
EP2653166A3 (en) * 2007-07-30 2014-08-27 Healor Ltd. Pharmaceutical composition and related methods
WO2009029678A1 (en) * 2007-08-27 2009-03-05 Kai Pharmaceuticals, Inc. PROTEIN KINASE C-δ INHIBITORS THAT PROTECT AGAINST CELLULAR INJURY AND INFLAMMATION AND PROMOTE ASTROCYTE PROLIFERATION
WO2009154169A1 (ja) * 2008-06-19 2009-12-23 学校法人近畿大学 ペプチド誘導体およびそれを含む涙液分泌促進組成物
WO2011083483A2 (en) * 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
EP2637684A4 (en) 2010-11-08 2014-05-07 Healor Ltd BUFFERED OPHTHALMIC COMPOSITIONS AND USER METHOD THEREFOR

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124553A1 (en) * 2007-05-04 2009-05-14 Mochly-Rosen Daria D Suppression of inflammation associated with transplantation using an epsilon PKC inhibitor
US20100092452A1 (en) * 2008-05-07 2010-04-15 The Regents Of The University Of California Replenishment and Enrichment of Ocular Surface Lubrication
WO2010029350A1 (en) * 2008-09-09 2010-03-18 University Of East Anglia Treatment of fibrotic eye disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZAGON IS: "Use of topical insulin to normalize corneal epithleial healing in diabetes mellitus", 《ARCH OPHTHALMOL》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104940904A (zh) * 2015-05-27 2015-09-30 北京爱特普科技有限公司 一种腔体粘膜微生态调节剂及其制备方法
CN109640966A (zh) * 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
WO2024148654A1 (zh) * 2023-01-09 2024-07-18 维眸生物科技(浙江)有限公司 一种含vvn539的眼用组合物及其用途

Also Published As

Publication number Publication date
RU2013117209A (ru) 2014-10-27
EP2637684A2 (en) 2013-09-18
US20120264681A1 (en) 2012-10-18
CA2812164A1 (en) 2012-05-18
WO2012063237A2 (en) 2012-05-18
US20150094260A1 (en) 2015-04-02
AU2011327785A1 (en) 2013-03-07
EP2637684A4 (en) 2014-05-07
JP2013543862A (ja) 2013-12-09
WO2012063237A3 (en) 2012-11-22
CN104758921A (zh) 2015-07-08
EP2944319A1 (en) 2015-11-18

Similar Documents

Publication Publication Date Title
CN103249429A (zh) 缓冲的眼用组合物以及使用其的方法
Lanier et al. Review of approaches for increasing ophthalmic bioavailability for eye drop formulations
US20190282398A1 (en) Therapeutics dispensing device and methods of making same
Huang et al. Combination of dexamethasone and Avastin® by supramolecular hydrogel attenuates the inflammatory corneal neovascularization in rat alkali burn model
KR101560429B1 (ko) 눈의 통증을 치료 또는 예방하기 위한 케토롤락 트로메타민 조성물
ES2330762T3 (es) Uso de etabonato de loteprednol para el tratamiento del ojo seco.
SA521430043B1 (ar) صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل) - بنزونيتريل
CN105848651A (zh) 干眼症治疗用滴眼剂
US20210315805A1 (en) Ketorolac compositions for corneal wound healing
JP2023530189A (ja) 高眼圧症および緑内障の治療および予防のためのヒアルロン酸に基づく製剤
TW201350109A (zh) 用於降低眼部不適的方法及組成物
US20200188297A1 (en) LXR Agonist in Topical Ophthalmic Formulation for Treatment of Dry-Eye Disorder
Philip Nanotechnology-based therapeutic strategies for dry eye disease
CN104721130B (zh) 一种布林佐胺包合物眼用制剂及其制备方法
CN118510520A (zh) 用于治疗眼部疾病的霉酚酸和/或倍他米松的药物组合物
HK1182955A (en) Buffered ophthalmic compositions and methods of use thereof
Parekh Solid Dosage Forms for Ophthalmic Products
Daphna et al. Research Article Therapeutic HL-Contact Lens versus Standard Bandage Contact Lens for Corneal Edema: A Prospective, Multicenter, Randomized, Crossover Study
Al-Saedi Formulation and in vitro evaluation of cyclosporine A inserts prepared using HPMC for treating dry eye disease
JP2023518140A (ja) 緑内障手術後の瘢痕化を減少させるためのバルプロ酸の使用
Renukuntla et al. Drug Delivery to Anterior Segment of the Eye
Biswas Ophthalmic Drug Delivery Systems: An Update

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1182955

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130814

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1182955

Country of ref document: HK